CancerVAX Appoints Dr. George Kemble as Senior Scientific Advisor
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2d ago
0mins
Source: Yahoo Finance
- New Advisor Appointment: CancerVax has appointed Dr. George Kemble, a former AstraZeneca executive, as Senior Scientific Advisor, leveraging his extensive experience in virology and vaccines to advance the company's cancer treatment platform.
- Industry Background: Dr. Kemble previously served as CEO at Sagimet Biosciences, where he led multiple cancer treatment initiatives, particularly in developing fatty acid synthase inhibitors, showcasing his deep expertise in the biopharmaceutical sector.
- Innovative Treatment Concept: CancerVax's platform disguises cancer cells as foreign viruses to harness the immune system for attack, and Dr. Kemble's involvement is expected to enhance this innovative strategy and improve treatment efficacy.
- Scientific Leadership: George Katibah, Chief Scientific Officer of CancerVax, noted that Dr. Kemble's expertise will provide critical insights for the company's progress in cancer immunotherapy, aiding in translating fundamental immunology into practical therapies.
Analyst Views on SGMT
Wall Street analysts forecast SGMT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SGMT is 28.57 USD with a low forecast of 25.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.090
Low
25.00
Averages
28.57
High
35.00
Current: 6.090
Low
25.00
Averages
28.57
High
35.00
About SGMT
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis. The Company is also exploring the use of its FASN inhibitors, which include denifanstat and its pipeline product candidate, TVB-3567, in acne and in select forms of cancer. Denifanstat is being tested in China by its license partner, Ascletis BioScience Co. Ltd., for moderate to severe acne vulgaris and recurrent glioblastoma multiforme in combination with bevacizumab.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
